Evolus, Inc. - Common Stock, par value $0.00001 per share (EOLS)

CUSIP: 30052C107

Q1 2024 13F Holders as of 31 Mar 2024

Holder snapshot 7 signals
Share change
+3,712,416
Put/Call ratio
103%
SEC-reported price per share
$14.00
Number of holders
160
Value change
+$53,544,087
Number of buys
87
Open additional details 1 more signal available
Number of sells
63
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
65,660,377

Security key

30052C107

Report period

Q1 2024

Institutions

160

Top holders

10

Ownership snapshot

Top reported holders of EOLS - Evolus, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Alphaeon 1 LLC
Disclosed value leader
Stonepine Capital Managem...
Comparable rows
0/15
Latest evidence
31 Dec 2023
3/4/5 13F Highest disclosed value: $56,156,532 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Stonepine Capital Management, LLC has the largest disclosed position value at $56.16M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Stonepine Capital Management, LLC's linked filing trail.
Disclosed position value Top 5
Alphaeon 1 LLC $35.4M
Medytox Inc. $25.36M
Stonepine Capital Management, LLC $56.16M
PERCEPTIVE ADVISORS LLC $41.73M
BlackRock Finance, Inc. $35.16M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Alphaeon 1 LLC
3/4/5
10%+ Owner
—
denominator unverified
$35,404,916
4,214,871 shares
— 17 Feb 2023
Medytox Inc.
3/4/5
Former 10% Owner
—
denominator unverified
$25,359,945
3,381,326 shares
— 16 Oct 2023
Stonepine Capital Management, LLC
13F
Company
13F
—
denominator unverified
$56,156,532
5,333,004 shares
— 31 Dec 2023
PERCEPTIVE ADVISORS LLC
13F
Company
13F
—
denominator unverified
$41,734,855
3,963,424 shares
— 31 Dec 2023
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$35,163,640
3,339,377 shares
— 31 Dec 2023
TANG CAPITAL MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$32,615,611
3,097,399 shares
— 31 Dec 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
160
Shares
49,347,816
Rows available
160
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders
160
Q1 2024 holders
160
Holder diff
0
Investor Q1 2024 Shares Q1 2024 Shares Share Diff Share Chg % Q1 2024 value Q1 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .